NCT07299955 is a Phase 1 clinical trial of Bmab3000 in Healthy Male Participants, sponsored by Biocon Biologics UK PLC.

Who is sponsoring NCT07299955?

NCT07299955 is sponsored by Biocon Biologics UK PLC.

What drugs are being tested in NCT07299955?

Interventions in NCT07299955: Bmab3000, Herceptin Hylecta®.

What condition does NCT07299955 study?

NCT07299955 studies Healthy Male Participants.

Is NCT07299955 still recruiting?

NCT07299955 is currently recruiting now. Last updated 8 April 2026.

Last reviewed 2026-04-08 · How we verify

NCT07299955

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1 Comparative Study to Evaluate Pharmacokinetics, Immunogenicity, Safety and Tolerability of Bmab3000 and Herceptin Hylecta® After a Single 600 mg SC Injection in Healthy Male Volunteers

Recruiting now Phase 1 Last updated 8 April 2026

What this trial tests

Phase 1 trial testing Bmab3000 in Healthy Male Participants in 150 participants. Currently enrolling.

Timeline

28 February 2026

Primary endpoint
30 June 2026

30 June 2026

Quick facts

Lead sponsor	Biocon Biologics UK PLC
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	150
Start date	28 February 2026
Primary completion	30 June 2026
Estimated completion	30 June 2026
Sites	1 location across New Zealand

Drugs / interventions tested

Bmab3000 — full drug profile →
Herceptin Hylecta® — full drug profile →

Conditions studied

Healthy Male Participants — all drugs for Healthy Male Participants →

Sponsor

Biocon Biologics UK PLC — full company profile →

Who can join

Adults 18 to 65, male only, with Healthy Male Participants. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I study is to compare the pharmacokinetics (PK), immunogenicity, safety, and tolerability of Bmab3000 (test) and Herceptin Hylecta (reference) after a single subcutaneous (s.c.) dose in healthy male volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Biocon Biologics UK PLC trials

Trials by the same sponsor.

NCT07476326 — Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07299955 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biocon Biologics UK PLC
Last refreshed: 8 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07299955.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing